Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USA;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USADepartment of Orthopaedic Surgery Kyoto University Graduate School of Medicine Sakyo Kyoto 606-8507 JapanDepartment of Advanced Medicine for Rheumatic Diseases Kyoto University Graduate School of Medicine Sakyo Kyoto 606-8507 Japan;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USA;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USA;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USA;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USA;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USADepartment of Biology Chungbuk National University Cheongju 28644 Republic of Korea;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USA;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USABCMB Allied Program Weill Cornell Graduate School of Medical Science New York NY 10021 USA;
Arthritis and Tissue Degeneration Program and David Z.Rosensweig Genomics Research Center Hospital for Special Surgery New York NY 10021 USAImmunology and Microbial Pathogenesis Program Weill Cornell Graduate School of Medical Science New York NY 10021 USA;
osteoclast; MEF2C; pathologic;